Dr. Andtbacka on Ongoing Trials With Oncolytic Immunotherapies in Melanoma

Robert H. I. Andtbacka, MD
Published: Tuesday, Feb 09, 2016



Robert Andtbacka, MD, associate professor, Division of Surgical Oncology, Department of Surgery, University of Utah School of Medicine, discusses ongoing clinical trials investigating oncolytic immunotherapies as treatment for melanoma.

Oncolytic immunotherapies have been a research focus in the field of melanoma for the past few years, Andtbacka says. The agents, which are injected directly into tumors, are being investigated as both monotherapy and as part of combination regimens.

Andtbacka says oncolytic immunotherapies are also being studied in the neoadjuvant setting for patients with resectable disease.
SELECTED
LANGUAGE


Robert Andtbacka, MD, associate professor, Division of Surgical Oncology, Department of Surgery, University of Utah School of Medicine, discusses ongoing clinical trials investigating oncolytic immunotherapies as treatment for melanoma.

Oncolytic immunotherapies have been a research focus in the field of melanoma for the past few years, Andtbacka says. The agents, which are injected directly into tumors, are being investigated as both monotherapy and as part of combination regimens.

Andtbacka says oncolytic immunotherapies are also being studied in the neoadjuvant setting for patients with resectable disease.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x